Radiographic Local Tumor Control and Pain Palliation of Sarcoma Metastases within the Musculoskeletal System with Percutaneous Thermal Ablation
- 18 Downloads
To evaluate the effectiveness of percutaneous image-guided thermal ablation in achieving local tumor control and pain palliation of sarcoma metastases within the musculoskeletal system.
Materials and Methods
Retrospective review of 64 sarcoma metastases within the musculoskeletal system in 26 women and 15 men (total = 41) treated with ablation between December 2011 and August 2016 was performed. Mean age of the cohort was 42.9 years ± 16.0 years. Two subgroups were treated: oligometastatic disease (n = 13) and widely metastatic disease (n = 51). A variety of sarcoma histologies were treated with average tumor volume of 42.5 cm3 (range 0.1–484.7 cm3). Pain scores were recorded before and 4 weeks after therapy for 59% (38/64) of treated lesions. Follow-up imaging was evaluated for local control and to monitor sites of untreated disease as an internal control. Fifty-eight percent (37/64) were lost to imaging follow-up at varying time points over a year. Complication rate was 5% (3/64; one minor and two major events).
One-year local tumor control rates were 70% (19/27) in all patients, 67% (12/18) in the setting of progression of untreated metastases, and 100% (10/10) in the setting of oligometastatic disease. Median pain scores decreased from 8 (interquartile range 5.0–9.0) to 3 (interquartile range 0.1–4.0) 1 month after the procedure (P < 0.001).
Image-guided percutaneous ablation is an effective option for local tumor control and pain palliation of metastatic sarcomas within the musculoskeletal system. Treatment in the setting of oligometastatic disease offers potential for remission.
Level of Evidence
Level 4, Retrospective Review.
KeywordsRadiofrequency ablation Cryoablation Local tumor control Pain palliation Sarcoma Cementoplasty
Compliance with Ethical Standards
Conflict of interest
Jack W. Jennings is a paid consultant and is on the medical advisory board and speaker panel for Merit Medical Inc. and Medtronic.
- 23.National Cancer Institute (U.S.). Common Terminology Criteria for Adverse Events v4.0 (CTCAE). U.S. Depart of Health and Human Serv, Nat Inst of Health, Nat Canc Inst, 2009; NIH pub #09-7473.Google Scholar
- 24.Bang HJ, Littrup PJ, Currier BP, et al. Percutaneous cryoablation of metastatic lesions from colorectal cancer: efficacy and feasibility with survival and cost-effectiveness observations. ISRN Min Invasive Surg. 2012;2012.Google Scholar